Axsome Therapeutics, Inc. (AXSM) shareholders
Close on Nov 17, 2026Market cap $7.12BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Roderick Wong, M.D. Joint filing with RTW Investments, LP (6.00%) | 2,922,729 | 6.00% | 13G (passive) amendment | Mar 31, 2025 |
| BlackRock, Inc. | 2,736,503 | 5.30% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AXSM | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 3,103,708 | 5.93% | $759.69M | −809,136 | 0.01% |
| Vanguard Portfolio Management LLC | 1,983,514 | 3.79% | $485.50M | −74,656 | 0.02% |
| Vanguard Capital Management LLC | 1,965,086 | 3.75% | $480.99M | +27,334 | 0.01% |
| Invesco Ltd. | 1,671,684 | 3.19% | $409.18M | +374,006 | 0.03% |
| FMR LLC | 1,539,163 | 2.94% | $376.74M | −27,832 | 0.02% |
| Geode Capital Management, LLC | 967,172 | 1.85% | $236.79M | −195,809 | 0.01% |
| Assenagon Asset Management S.A. | 909,364 | 1.74% | $222.59M | +43,406 | 0.14% |
| Morgan Stanley | 804,082 | 1.54% | $196.82M | +327,381 | 0.01% |
| State Street Corp | 785,661 | 1.50% | $192.29M | −201,148 | 0.01% |
| Deep Track Capital, LP | 700,000 | 1.34% | $171.34M | −400,000 | 2.49% |
| Two Sigma Investments, LP | 669,478 | 1.28% | $163.87M | +346,700 | 0.12% |
| Franklin Resources Inc | 668,373 | 1.28% | $163.60M | +229,883 | 0.04% |
| Wellington Management Group Llp | 653,920 | 1.25% | $160.06M | −491,386 | 0.03% |
| Alethea Capital Management, LLC | 648,756 | 1.24% | $158.80M | −358 | 65.78% |
| Price T Rowe Associates Inc /Md/ | 642,893 | 1.23% | $157.36M | −674,166 | 0.02% |
| D. E. Shaw & Co., Inc. | 604,753 | 1.15% | $148.03M | +1,288 | 0.07% |
| Millennium Management LLC | 556,088 | 1.06% | $136.11M | +535,330 | 0.05% |
| Nomura Asset Management International Inc. | 539,407 | 1.03% | $132.03M | −273,402 | 0.20% |
| Norges Bank | 514,266 | 0.98% | $125.88M | New | 0.01% |
| First Trust Advisors LP | 482,061 | 0.92% | $117.99M | −95,418 | 0.07% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 505 | 39M | 73.8% | 139 / 161 | 157 / 40 | 8M | 7M |
| Q1 2026 | 410 | 38M | 72.4% | 71 / 146 | 142 / 53 | 9M | 5M |
| Q4 2025 | 399 | 38M | 71.9% | 87 / 139 | 122 / 34 | 6M | 6M |
| Q3 2025 | 355 | 37M | 71.5% | 49 / 146 | 105 / 40 | 5M | 5M |
| Q2 2025 | 348 | 38M | 72.3% | 55 / 152 | 92 / 57 | 6M | 6M |
| Q1 2025 | 353 | 38M | 71.7% | 92 / 103 | 115 / 28 | 8M | 8M |
| Q4 2024 | 292 | 37M | 71.0% | 61 / 91 | 90 / 40 | 5M | 6M |
| Q3 2024 | 280 | 39M | 74.3% | 48 / 83 | 95 / 22 | 6M | 5M |
| Q2 2024 | 257 | 41M | 78.2% | 33 / 78 | 97 / 33 | 7M | 7M |
| Q1 2024 | 259 | 41M | 78.0% | 44 / 97 | 74 / 26 | 6M | 5M |
| Q4 2023 | 244 | 39M | 75.2% | 44 / 70 | 88 / 24 | 5M | 4M |
| Q3 2023 | 226 | 38M | 72.3% | 26 / 87 | 71 / 28 | 5M | 3M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
379 funds held AXSM in Q2 2026, 40% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AXSM | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,388,721 | 2.65% | $339.92M | 0.01% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 1,003,488 | 1.92% | $245.62M | 0.13% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 578,233 | 1.10% | $141.53M | 0.30% | Jun 30, 2026 |
| Vanguard Explorer Fund | 531,004 | 1.01% | $115.75M | 0.52% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 495,762 | 0.95% | $121.35M | 0.12% | Jun 30, 2026 |
| Invesco Discovery Fund | 468,539 | 0.89% | $109.86M | 1.40% | May 31, 2026 |
| Nomura Small Cap Core Fund | 430,250 | 0.82% | $100.89M | 1.83% | May 29, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 426,122 | 0.81% | $104.30M | 3.71% | Jun 30, 2026 |
| iShares Biotechnology ETF | 305,148 | 0.58% | $74.69M | 0.82% | Jun 30, 2026 |
| Franklin Dynatech Fund | 300,000 | 0.57% | $73.43M | 0.24% | Jun 30, 2026 |
| Select Biotechnology Portfolio | 286,580 | 0.55% | $67.20M | 1.28% | May 31, 2026 |
| Eventide Gilead Fund | 257,138 | 0.49% | $62.94M | 1.83% | Jun 30, 2026 |
| iShares Russell Mid-Cap Growth ETF | 254,745 | 0.49% | $62.35M | 0.29% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 218,156 | 0.42% | $51.15M | 0.12% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 212,917 | 0.41% | $49.92M | 0.28% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Herriot Tabuteau | Chief Executive Officer, Director, 10% owner | 7,356,389 | 14.04% | Aug 7, 2026 |
| Mark L. Jacobson | Chief Operating Officer | 10,000 | 0.02% | Sep 3, 2026 |
| Nick Pizzie | Chief Financial Officer | 43,355 | 0.08% | Jun 9, 2026 |
| Ari Maizel | Chief Commercial Officer | 7,500 | 0.01% | Apr 23, 2026 |
| Hunter R. Murdock | General Counsel | 6,014 | 0.01% | Apr 23, 2026 |
| Roger Jeffs | Director | 105,279 | 0.20% | Jun 11, 2026 |
| Mark Coleman | Director | 434,245 | 0.83% | Jun 10, 2026 |
| Susan Mahony | Director | 829 | 0.00% | Jun 10, 2026 |
| Mark E. Saad | Director | 11,731 | 0.02% | Jun 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark L. Jacobson Chief Operating Officer | Sep 3, 2026 | Option exercise | +10,000 | $12.95 | $129.50K | 10,000 |
| Mark L. Jacobson Chief Operating Officer | Sep 3, 2026 | Sale(10b5-1 plan) | −10,000 | $208.65 | $2.09M | 0 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 6, 2026 | Option exercise | +4,660 | $4.95 | $23.07K | 11,889 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 6, 2026 | Sale(10b5-1 plan) | −4,660 | $213.95 | $997.01K | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 5, 2026 | Option exercise | +45,004 | $4.95 | $222.77K | 52,233 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Aug 5, 2026 | Sale(10b5-1 plan) | −45,004 | $212.01 | $9.54M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jul 1, 2026 | Sale(10b5-1 plan) | −49,666 | $240.25 | $11.93M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jul 1, 2026 | Option exercise | +49,666 | $4.95 | $245.85K | 56,895 |
| Roger Jeffs Director | Jun 11, 2026 | Sale(10b5-1 plan) | −286 | $249.12 | $71.25K | 58,367 |
| Roger Jeffs Director | Jun 10, 2026 | Sale(10b5-1 plan) | −286 | $246.18 | $70.41K | 58,653 |
| Mark Coleman Director | Jun 10, 2026 | Sale(10b5-1 plan) | −643 | $249.00 | $160.11K | 30,389 |
| Susan Mahony Director | Jun 10, 2026 | Sale(10b5-1 plan) | −300 | $246.18 | $73.85K | 829 |
| Susan Mahony Director | Jun 9, 2026 | Sale(10b5-1 plan) | −300 | $237.21 | $71.16K | 1,129 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jun 9, 2026 | Sale(10b5-1 plan) | −49,670 | $241.01 | $11.97M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jun 9, 2026 | Option exercise | +49,670 | $4.95 | $245.87K | 56,899 |
| Nick Pizzie Chief Financial Officer | Jun 9, 2026 | Sale(10b5-1 plan) | −33,000 | $240.09 | $7.92M | 42,867 |
| Nick Pizzie Chief Financial Officer | Jun 9, 2026 | Option exercise | +33,000 | $3.50 | $115.50K | 75,867 |
| Roger Jeffs Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 58,939 |
| Mark Coleman Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 31,032 |
| Susan Mahony Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 1,429 |
| Mark E. Saad Director | Jun 8, 2026 | Option exercise | +1,429 | – | – | 11,431 |
| Mark Coleman Director | Jun 2, 2026 | Sale(10b5-1 plan) | −5,537 | $223.39 | $1.24M | 29,603 |
| Mark Coleman Director | Jun 1, 2026 | Sale(10b5-1 plan) | −6,000 | $230.30 | $1.38M | 35,140 |
| Mark Coleman Director | May 29, 2026 | Sale(10b5-1 plan) | −6,000 | $233.46 | $1.40M | 41,140 |
| Mark L. Jacobson Chief Operating Officer | May 5, 2026 | Option exercise | +233 | $12.95 | $3.02K | 233 |
| Mark L. Jacobson Chief Operating Officer | May 5, 2026 | Sale(10b5-1 plan) | −233 | $228.18 | $53.17K | 0 |
| Mark L. Jacobson Chief Operating Officer | May 4, 2026 | Sale(10b5-1 plan) | −4,517 | $227.94 | $1.03M | 0 |
| Mark L. Jacobson Chief Operating Officer | May 4, 2026 | Option exercise | +4,517 | $12.95 | $58.50K | 4,517 |
| Ari Maizel Chief Commercial Officer | Apr 22, 2026 | Option exercise | +7,500 | $70.73 | $530.48K | 7,500 |
| Ari Maizel Chief Commercial Officer | Apr 22, 2026 | Sale(10b5-1 plan) | −7,500 | $182.42 | $1.37M | 0 |
| Mark Coleman Director | Feb 26, 2026 | Sale(10b5-1 plan) | −25,000 | $161.11 | $4.03M | 47,140 |
| Mark L. Jacobson Chief Operating Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −35,378 | $161.88 | $5.73M | 0 |
| Mark L. Jacobson Chief Operating Officer | Feb 26, 2026 | Option exercise | +35,378 | $2.85 | $100.83K | 35,378 |
| Mark Coleman Director | Feb 23, 2026 | Option exercise | +6,250 | $4.95 | $30.94K | 72,140 |
| Mark Coleman Director | Feb 20, 2026 | Option exercise | +12,485 | $4.95 | $61.80K | 65,890 |
| Mark Coleman Director | Feb 10, 2026 | Option exercise | +5,193 | $8.02 | $41.65K | 53,405 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Feb 2, 2026 | Option exercise | +32,410 | $8.02 | $259.93K | 39,639 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Feb 2, 2026 | Sale(10b5-1 plan) | −32,410 | $185.60 | $6.02M | 7,229 |
| Nick Pizzie Chief Financial Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −12,000 | $187.92 | $2.26M | 42,588 |
| Nick Pizzie Chief Financial Officer | Jan 22, 2026 | Option exercise | +12,000 | $3.50 | $42.00K | 54,588 |
| Ari Maizel Chief Commercial Officer | Jan 21, 2026 | Option exercise | +7,500 | $70.73 | $530.48K | 7,500 |
| Ari Maizel Chief Commercial Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −7,500 | $184.44 | $1.38M | 0 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 7, 2026 | Option exercise | +31,261 | $8.02 | $250.71K | 38,490 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 7, 2026 | Sale(10b5-1 plan) | −31,261 | $170.38 | $5.33M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 6, 2026 | Option exercise | +29,450 | $8.02 | $236.19K | 36,679 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 6, 2026 | Sale(10b5-1 plan) | −29,450 | $172.33 | $5.08M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 5, 2026 | Sale(10b5-1 plan) | −78,703 | $171.28 | $13.48M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Jan 5, 2026 | Option exercise | +78,703 | $8.02 | $631.20K | 85,932 |
| Mark E. Saad Director | Dec 31, 2025 | Option exercise | +31,346 | $4.95 | $155.16K | 41,348 |
| Mark E. Saad Director | Dec 31, 2025 | Sale(10b5-1 plan) | −31,346 | $165.18 | $5.18M | 10,002 |
| Mark E. Saad Director | Dec 31, 2025 | Sale(10b5-1 plan) | −6,231 | $165.18 | $1.03M | 10,002 |
| Mark E. Saad Director | Dec 31, 2025 | Option exercise | +6,231 | $8.02 | $49.97K | 16,233 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 4, 2025 | Sale(10b5-1 plan) | −10,558 | $148.18 | $1.56M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 4, 2025 | Option exercise | +10,558 | $8.02 | $84.68K | 17,787 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 3, 2025 | Option exercise | +20,163 | $8.02 | $161.71K | 27,392 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 3, 2025 | Sale(10b5-1 plan) | −20,163 | $146.94 | $2.96M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 2, 2025 | Option exercise | +49,252 | $8.02 | $395.00K | 56,481 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Dec 2, 2025 | Sale(10b5-1 plan) | −49,252 | $144.59 | $7.12M | 7,229 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Nov 5, 2025 | Option exercise | +21,775 | $8.02 | $174.64K | 29,004 |
| Herriot Tabuteau Chief Executive Officer, Director, 10% owner | Nov 5, 2025 | Sale(10b5-1 plan) | −21,775 | $134.49 | $2.93M | 7,229 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Axsome Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 20,192 shares on Sep 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Mark L. Jacobson Officer | Sep 3, 2026 | 10,000 | $2.08M | Sep 3, 2026 | Acquired as compensation -- Stock Options |
| Herriot Tabuteau Officer | Aug 6, 2026 | 4,660 | $979.21K | Aug 6, 2026 | Acquired as compensation -- Stock Options |
| Herriot Tabuteau Officer | Aug 5, 2026 | 45,004 | $9.58M | Aug 5, 2026 | Acquired as compensation -- Stock Options |
| Herriot Tabuteau Officer | Jul 1, 2026 | 49,666 | $11.95M | Jul 1, 2026 | Acquired as compensation -- Stock Options |
| Roger Jeffs Director | Jun 11, 2026 | 286 | $71.25K | Jun 11, 2026 | Restricted Stock Lapse |
| Mark Coleman Director | Jun 10, 2026 | 643 | $160.11K | Jun 10, 2026 | Restricted Stock Lapse |
| Roger Jeffs Director | Jun 10, 2026 | 286 | $70.41K | Jun 10, 2026 | Restricted Stock Lapse |
| Susan Mahony Director | Jun 10, 2026 | 300 | $73.85K | Jun 10, 2026 | Restricted Stock Lapse |
| Herriot Tabuteau Officer | Jun 9, 2026 | 49,670 | $12.20M | Jun 9, 2026 | Acquired as compensation -- Stock Options |
| Nick Pizzie Officer | Jun 9, 2026 | 33,000 | $7.92M | Jun 9, 2026 | Employee Stock Option Exercise |
| Susan Mahony Director | Jun 9, 2026 | 300 | $71.16K | Jun 9, 2026 | Restricted Stock Lapse |
| Mark Coleman Director | Jun 2, 2026 | 5,537 | $1.24M | Jun 2, 2026 | Exercise and Hold |
| Mark Coleman Director | Jun 1, 2026 | 6,000 | $1.38M | Jun 1, 2026 | Exercise and Hold |
| Mark Coleman Director | May 29, 2026 | 6,000 | $1.40M | May 29, 2026 | Exercise and Hold |
| Mark L. Jacobson Officer | May 5, 2026 | 233 | $51.97K | May 5, 2026 | Acquired as compensation -- Stock Options |
Congress trades
1 trade in Axsome Therapeutics reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Bought | Jun 16, 2022 | $15K–50K | Jul 28, 2022 |
See a number that looks wrong?